ARMI - KN

Clinical trials are everything in medical research. In light of that, we make it a point to stay abreast of any new information regarding stem cell clinical trials. The more researchers look into the power of stem cells, the more we are learning of their incredible healing potential. A case in point is a new cancer treatment that has just entered clinical trials.

History suggests that measles is a zoonotic disease that first emerged in human beings sometime between 500 and 1200 A.D. In the centuries since, the world has seen numerous measles epidemics that have claimed untold numbers of lives. Measles has been so deadly in some places that, if you had told doctors 100 years ago that the measles virus would eventually go on to improve human health, they would have thought you were crazy. Well, guess what? It turns out to be true.

Scott Gottlieb’s FDA has implemented many policies in recent years that look to fast-track certain kinds of regenerative medicine procedures so that said procedures can get to market faster. One example of this fast tracking is a procedure for treating rotator cuff injuries that the FDA recently confirmed as being safe.

One of the things we are sure to mention in our PRP and stem cell training is the fact that health insurance plans do not cover the procedures. As such, patients are left to pay for treatment out of pocket. This is both good and bad.

An interesting July article from Finance Magnates explored the dual concepts of stem cell therapy and virtual medicine. Though the article treated the two separately, it got us to thinking about what it would be like to combine them to treat a person suffering from some sort of musculoskeletal injury or disease. A sports injury or osteoarthritis immediately come to mind.

We have observed an interesting trend in regenerative medicine over last 12 months or so: despite plenty of bad press fueled by a small number of shady stem cell clinics, interest in stem cell therapies continues to grow among both clinicians and patients alike. We have seen it first-hand as a steady stream of doctors continue signing up to take our stem cell therapy training courses. So what’s driving the interest? Clinical trials.

It is not uncommon for doctors to contact us only to then decide that stem cell training is not for them. We have no problem with that. Not every clinician fully embraces the idea of regenerative medicine. If you are among that group of doctors, we want to challenge your thinking with a hypothetical question: if put in the position, would you choose joint replacement over stem cell therapy?

If you are planning to join the Advanced Regenerative Medicine Institute (ARMI) for one of our stem cell therapy training courses, congratulations. You are going to get some of the best training in the industry. While you’re with us, you will learn everything you need to know to offer your patients effective stem cell and PRP treatments for a variety of conditions.

New research suggests that the age of stem cell donors matters for therapies where donors and recipients are different people. That would seem to make sense given the strength of stem cells in relation to a person’s age. But would the same thing be observed with autologous stem cell treatments? In other words, does the age of a person receiving stem cell treatment for osteoarthritis partly determine the efficacy of that treatment?

Assuming you are a doctor, do you remember the wandering of your thoughts in the early days of your residency? You wondered what life would be like once your residency was complete. You wondered where you would go, what you would do, and how you would transition from education into career mode. We see something similar with our stem cell training courses, albeit on a much smaller scale.